ZeroHarm Sciences Secures Rs 65 Cr for Nano-Nutraceuticals

ZeroHarm Sciences recently raised Rs 65 crore to scale its innovative plant-based nutraceutical brand. Consequently, this capital infusion from Kotak Life Sciences Fund and Alkemi Growth Capital marks a major milestone. The company intends to enhance its research capabilities and global reach.

Advancements in the Plant-based Nutraceutical Brand

Specifically, ZeroHarm uses proprietary nano-formulation technology to increase the bioavailability of its supplements. This method ensures that herbal actives are absorbed more effectively by the body. Furthermore, the firm is building India's first \"Trust over Promise\" health platform. This model correlates supplement use with measurable diagnostic results.

Strategic Growth and International Expansion

Additionally, the startup plans to enter markets in the US, UK, and the Middle East. ZeroHarm maintains a vertically integrated ecosystem, covering extraction, R&D, and manufacturing. Notably, this structure allows for strict quality control and standardized health outcomes. Because of these factors, investors see high potential in the company’s science-led approach.

Frequently Asked Questions

Q1: What is the \"Trust over Promise\" platform?

The \"Trust over Promise\" platform allows customers to see measurable health outcomes through before-and-after diagnostic testing.

Q2: How does nano-formulation technology benefit patients?

Nano-formulation breaks down herbal actives into ultra-fine particles, which significantly improves their absorption and efficacy compared to traditional supplements.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. ZeroHarm Sciences raises Rs 65 cr from Kotak Life Sciences Fund, Alkemi GrowthCapital - ETHealthworld


2. YourStory - ZeroHarm Sciences raises Rs 65 Cr led by Kotak Life Sciences Fund


3. Pharmabiz - Kotak Alts invests Rs. 400 million in Zeroharm Sciences